Stem Cell Clinic

Can we trust your doctor? – Video

Can we trust your doctor?
http://www.rejuvenare.com 1 888-988-5456 Many people who feel that stem cell therapy is the answer they have been searching for are concerned that, as of today, they need to travel for the simple procedure and they are unsure of the level of treatment they will receive. Recently the former head of a multi-national pharmaceutical company turned to Rejuvenare for help with the debilitating effects of Parkinson #39;s disease. In this short video clip - you will see the interview with his son and wife on their impression of the level of care their loved one received. This interview was done 2 days after the procedure. The improvement to their family member was apparent within hours - although they were all a little tired, they were also appreciative... Are you or someone you know a candidate for adult stem cell therapy? Visit http or call 888-988-5456 to find out.

By: Carlo Velarde

Read this article:
Can we trust your doctor? - Video

Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy – Video

Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy
Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy He is a known case of Myotonic MD with history of gradual onset of progressive lower extremities muscle weakness since age of 25 years. He also has history of delayed milestones. His weakness is progressive in nature. He falls while walking so walks with human support only. He has complaints of early fatigue and slurred speech due to tongue hypertrophy. He has atrophy of proximal muscles of all extremities. He has modified independence in almost all ADL. Neurologically, hypotonic, hyporeflexic. On examination: lower limb distal muscles are 0/5 on MMT while proximal muscles are having 2++/5 on MMT. Upper extremities left side proximal muscles are 1++/5 while right side proximal muscles are 3 #713;/5, distal muscles are 3++/5 in upper extremities. Functionally, modified independence in all ADL. On FIM he scores 99. After Stem Cell Treatment 1. His face looks more fresh. 2. His neck used to fall back previously but now he can control his neck well in each movement. 3. Back muscle strength has improved. 4. Bridging is better now. He can lift his back more up now which he couldn #39;t do at all. 5. His stamina has improved. 6. His shoulder strength has improved. Shoulder shrugging is better now. Active shoulder flexion, range of motion is more now. 7. Side lying to sitting he can do without any support which was not possible before. 8. Drooling of saliva from mouth in night is completely stopped. 9. His legs used ...

By: neurogenbsi

Read more from the original source:
Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy - Video

Myotonic Muscular Dystrophy Before and After Stem Cell Therapy – Video

Myotonic Muscular Dystrophy Before and After Stem Cell Therapy
Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy He is a known case of Myotonic MD with history of gradual onset of progressive lower extremities muscle weakness since age of 25 years. He also has history of delayed milestones. His weakness is progressive in nature. He falls while walking so walks with human support only. He has complaints of early fatigue and slurred speech due to tongue hypertrophy. He has atrophy of proximal muscles of all extremities. He has modified independence in almost all ADL. Neurologically, hypotonic, hyporeflexic. On examination: lower limb distal muscles are 0/5 on MMT while proximal muscles are having 2++/5 on MMT. Upper extremities left side proximal muscles are 1++/5 while right side proximal muscles are 3 #713;/5, distal muscles are 3++/5 in upper extremities. Functionally, modified independence in all ADL. On FIM he scores 99. After Stem Cell Treatment 1. His face looks more fresh. 2. His neck used to fall back previously but now he can control his neck well in each movement. 3. Back muscle strength has improved. 4. Bridging is better now. He can lift his back more up now which he couldn #39;t do at all. 5. His stamina has improved. 6. His shoulder strength has improved. Shoulder shrugging is better now. Active shoulder flexion, range of motion is more now. 7. Side lying to sitting he can do without any support which was not possible before. 8. Drooling of saliva from mouth in night is completely stopped. 9. His legs used ...

By: neurogenbsi

View original post here:
Myotonic Muscular Dystrophy Before and After Stem Cell Therapy - Video

Alternatives to knee replacement… fibroblast growth factor as an aid to stem cell cartilage repair – Video

Alternatives to knee replacement... fibroblast growth factor as an aid to stem cell cartilage repair
http://www.stemcellsarthritistreatment.com In our series on alternatives to knee replacement, let #39;s go over some of the growth factors needed for cartilage growth and maintenance... let #39;s talk about Fibroblast growth factor Fibroblast growth factors (FGF) are proteins that play a major role in the development of normal cartilage and bone. Genetic mutations that cause deficiencies of this protein result in significant skeletal abnormalities. In rat studies, FGF has demonstrated impressive abilities to stimulate cartilage repair in osteoarthritis. On the other hand FGF, under certain circumstances has been shown to inhibit the effects of other growth factors such as Insulin-like growth factor. Its use as an adjunctive ingredient in the application of mesenchymal stem cells for cartilage repair bears watching. http

By: Nathan Wei

Follow this link:
Alternatives to knee replacement... fibroblast growth factor as an aid to stem cell cartilage repair - Video

Obama: science should trump politics

President Obama, lifting an eight-year limit on federal funding of stem cell research, today portrayed his decision as part of a broader move to focus on science instead of politics.

Besides signing an executive order (read it here) reversing the Bush administration restrictions, Obama is also issuing a presidential memorandum (read it here) directing the head of the White House Office of Science and Technology Policy to develop a strategy for restoring scientific integrity to government decision making.

The goal, the president said: "To ensure that in this new administration, we base our public policies on the soundest science; that we appoint scientific advisers based on their credentials and experience, not their politics or ideology; and that we are open and honest with the American people about the science behind our decisions."

On embryonic stem cell research in particular, Obama acknowledged the religious-based opposition. But he said there is an ethical way to do such research.

"Rather than furthering discovery, our government has forced what I believe is a false choice between sound science and moral values," he said in the East Room of the White House, filled with advocates of stem cell research who cheered and applauded his annoucement. "In this case, I believe the two are not inconsistent. As a person of faith, I believe we are called to care for each other and work to ease human suffering. I believe we have been given a capacity and will to pursue this research -- and the humanity and conscience to do so responsibly."

Under Bush's order, taxpayer money could only be used for research on a small number of stem cell lines created before Aug. 9, 2001. Since, hundreds more stem cell lines have been created, but off-limits to federal funding.

While urging Congress to give more money to stem cell research, Obama is leaving to Congress the particularly controversial issue of whether taxpayer money should be used to experiment on embryos themselves. A congressional ban has been in place since 1996. He also made clear he opposes cloning for human reproduction.

The president also said that while stem cell research holds much promise in the treatment of spinal cord injuries, diabetes, and Parkinsons disease, there is no certainty.

"But that potential will not reveal itself on its own," Obama said. "Medical miracles do not happen simply by accident. They result from painstaking and costly research from years of lonely trial and error, much of which never bears fruit, and from a government willing to support that work.

"Ultimately, I cannot guarantee that we will find the treatments and cures we seek," he added. "No president can promise that. But I can promise that we will seek them -- actively, responsibly, and with the urgency required to make up for lost ground. Not just by opening up this new frontier of research today, but by supporting promising research of all kinds, including groundbreaking work to convert ordinary human cells into ones that resemble embryonic stem cells.

Read more here:
Obama: science should trump politics

Post Regenexx Stem Cell Treatment Results for JR’s Knee | Rejuv Medical, Minnesota – Video

Post Regenexx Stem Cell Treatment Results for JR #39;s Knee | Rejuv Medical, Minnesota
JR Burgess had a sport related knee injury. JR, went to Joel Baumgartner, MD to under go the stem cell injections for regenerative growth in his knee. Rejuv Medical has been following JR #39;s incredible results and recovery from the stem cell procedure that he has had done at Rejuv Medical of Saint Cloud, MN. http://www.rejuvmedical.com

By: Rejuv Medical

More here:
Post Regenexx Stem Cell Treatment Results for JR's Knee | Rejuv Medical, Minnesota - Video

Exceptional growth factors for cartilage in osteoarthritis- wnts! – Video

Exceptional growth factors for cartilage in osteoarthritis- wnts!
http://www.stemcellsarthritistreatment.com Cartilage repair and growth requires multiple key factors. Among these are Wnts. Wnts are proteins involved in the development of the skeleton and control cartilage growth. However, Wnt, if control of its effects are lost, can lead to diseases characterized by either excess bone and cartilage growth or inadequate bone and cartilage growth. So the judicious application of growth factors when it comes to stem cell treatment for osteoarthritis must take this into account. http

By: Nathan Wei

Read more from the original source:
Exceptional growth factors for cartilage in osteoarthritis- wnts! - Video

Osiris Therapeutics Establishes Direct Sales Force for Grafix®

COLUMBIA, Md.--(BUSINESS WIRE)--

Osiris Therapeutics, Inc. (OSIR), the leading company focused on developing and marketing stem cell products to treat serious medical conditions, announced today the introduction of a proprietary, direct sales force for Grafix, a premium cellular repair matrix for serious wounds including diabetic foot ulcers. The team of biologics sales professionals will initially be deployed in 10 major metropolitan areas throughout the United States and is expected to double over the coming year. Field representatives are supported by the Osiris medical affairs staff and a world-class team of stem cell scientists. This organization will enable Osiris to offer wound care practitioners a uniquely sophisticated service, only available from the cell therapy leader with 20 years of experience in the space.

"The decision to take Grafix into the wound care market with our own proprietary sales force was based upon a number of factors, including meaningful progress being made in reimbursement and favorable market dynamics," said Frank Czworka, Executive Director, Wound Care of Osiris Therapeutics. "However, the primary driver behind this initiative is the positive clinical results our physicians and surgeons are experiencing with Grafix. We continue to invest significant resources in Grafix to further demonstrate the clinical benefit it offers patients while favorably impacting overall healthcare costs. A product of this importance deserves a specialized, highly trained sales force."

In 2012, Osiris announced that it had received transitional pass-through status from the Center for Medicare & Medicaid Services ("CMS"), with C-Codes being designated for Grafix. More recently, specific codes were added to the Healthcare Common Procedure Coding System, or HCPCS code set, for GrafixPRIME and GrafixCORE. These product-specific Q-Codes will assist healthcare providers in seeking coverage for their patients. The Q-Codes that have been established for GrafixPRIME and GrafixCORE are Q4133 and Q4132, respectively.

Grafix has been the focus of active research in the fields of chronic wounds and burns. A 62-patient pilot study, presented at the Desert Foot 9th Annual High Risk Diabetic Foot Conference, was conducted in documented chronic wounds recalcitrant to treatment with standard of care and advanced therapies. The data demonstrated a 70% probability of wound closure by week 12, with a median time to closure of 5.6 weeks. Importantly, closure required a median of only 3 applications of Grafix, resulting in a potential savings over more costly treatments.

Clinical research for Grafix is continuing, including a multicenter, randomized, controlled trial for the treatment of non-healing diabetic foot ulcers. The study is actively enrolling up to 266 patients across 20 sites within the U.S.

About Grafix

Grafix is a human cellular repair matrix containing living stem cells for acute and chronic wound repair. It is a flexible, conforming membrane that provides a high quality source of living mesenchymal stem cells (MSCs) and growth factors directly to the site of the wound. Grafix is produced by BioSmartTM Intelligent Tissue Processing of human placental membrane. The manufacturing process maintains the integrity of the extracellular matrix, the viability of the neonatal MSCs, and the biologically active growth factors.

About Osiris Therapeutics

Osiris Therapeutics, Inc., having developed the worlds first approved stem cell drug, Prochymal, is the leading stem cell company. The company is focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets. In Biosurgery, Osiris currently markets Grafix for burns and chronic wounds, and Ovation for orthopedic applications. Osiris is a fully integrated company with capabilities in research, development, manufacturing and distribution of stem cell products. Osiris has developed an extensive intellectual property portfolio to protect the company's technology, including 50 U.S. and 156 foreign patents.

Read more here:
Osiris Therapeutics Establishes Direct Sales Force for Grafix®